{
    "2018-01-10": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Trial",
                        "Psoriasis",
                        "Cosentyx",
                        "Biosoimilar"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Rova-T",
                        "Label Expansion",
                        "Blockbuster Drug"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Analysts’ Recommendations for Incyte in January 2018",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommendations",
                        "Incyte"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 11, 2018",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Ex-Dividend",
                        "Date",
                        "Scheduled"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Stock",
                        "Roundup",
                        "Celgene",
                        "Acquire",
                        "Impact",
                        "J.P. Morgan",
                        "Healthcare",
                        "Conference"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "AbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Rova-T",
                        "Treatment",
                        "Small Cell Lung Cancer"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Imbruvica",
                        "Foundation Therapy",
                        "Hematologic Oncology"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ)",
                "features": {
                    "keywords": [
                        "Better Stock",
                        "AbbVie",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.55,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "AbbVie’s Rova-T: Solid Growth Driver for the Future?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Rova-T",
                        "Growth Driver",
                        "Future"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "AbbVie’s Position in the Growing Oncology Market in 2018",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Position",
                        "Oncology Market",
                        "2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Ex-Dividend Alert: AbbVie Raised its Dividend by 11%; Will Trade Ex-Dividend on January 11, 2018",
                "features": {
                    "keywords": [
                        "Ex-Dividend",
                        "Alert",
                        "AbbVie",
                        "Dividend",
                        "Raised"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "LPCN Awaits FDA Panel Vote Today, APHB Slumps, BGNE Crosses $100 Again",
                "features": {
                    "keywords": [
                        "LPCN",
                        "FDA",
                        "Panel Vote",
                        "APHB",
                        "Slumps",
                        "BGNE",
                        "$100"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-13",
                "original_text": "AbbVie's Upadacitinib Gains Breakthrough Therapy Designation",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Breakthrough",
                        "Therapy",
                        "Designation"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}